首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   534篇
  免费   40篇
  国内免费   20篇
妇产科学   2篇
基础医学   6篇
临床医学   16篇
内科学   8篇
皮肤病学   1篇
神经病学   8篇
特种医学   15篇
外科学   3篇
综合类   45篇
预防医学   8篇
药学   475篇
中国医学   3篇
肿瘤学   4篇
  2023年   3篇
  2022年   5篇
  2021年   10篇
  2020年   9篇
  2019年   8篇
  2018年   9篇
  2017年   7篇
  2016年   8篇
  2015年   9篇
  2014年   22篇
  2013年   57篇
  2012年   40篇
  2011年   49篇
  2010年   48篇
  2009年   37篇
  2008年   51篇
  2007年   56篇
  2006年   46篇
  2005年   24篇
  2004年   15篇
  2003年   11篇
  2002年   9篇
  2001年   3篇
  2000年   10篇
  1999年   7篇
  1998年   5篇
  1997年   1篇
  1996年   2篇
  1995年   3篇
  1994年   6篇
  1993年   2篇
  1992年   1篇
  1991年   2篇
  1990年   2篇
  1989年   6篇
  1988年   1篇
  1987年   3篇
  1986年   4篇
  1985年   1篇
  1984年   1篇
  1983年   1篇
排序方式: 共有594条查询结果,搜索用时 15 毫秒
1.

Background:

Decreases in the bioavailability of rifampicin (RFP) can lead to the development of drug resistance and treatment failure. Therefore, we investigated the relative bioavailability of RFP from one four-drug fixed-dose combination (FDC; formulation A) and three two-drug FDCs (formulations B, C, and D) used in China, compared with RFP in free combinations of these drugs (reference), in healthy volunteers.

Methods:

Eighteen and twenty healthy Chinese male volunteers participated in two open-label, randomized two-period crossover (formulations A and C) or one three-period crossover (formulations B and D) study, respectively. The washout period between treatments was 7 days. Bioequivalence was assessed based on 90% confidence intervals, according to two one-sided t-tests. All analyses were done with DAS 3.1.5 (Mathematical Pharmacology Professional Committee of China, Shanghai, China).

Results:

Mean pharmacokinetic parameter values of RFP obtained for formulations A, B, C, and D products were 11.42 ± 3.41 μg/ml, 7.86 ± 5.78 μg/ml, 13.05 ± 6.80 μg/ml, and 16.18 ± 3.87 μg/ml, respectively, for peak plasma concentration (Cmax), 91.43 ± 30.82 μg·h−1 ·ml−1, 55.49 ± 37.58 μg·h−1 ·ml−1, 96.50 ± 47.24 μg·h−1 ·ml−1, 101.47 ± 33.07 μg·h−1 ·ml−1, respectively, for area under the concentration-time curve (AUC0−24 h).

Conclusions:

Although the concentrations of RFP for formulations A, C, and D were within the reported acceptable therapeutic range, only formulation A was bioequivalent to the reference product. The three two-drug FDCs (formulations B, C and D) displayed inferior RFP bioavailability compared with the reference (Chinese Clinical Trials registration number: ChiCTR-TTRCC-12002451).  相似文献   
2.
In clinical endpoint bioequivalence (BE) studies, the primary analysis for assessing equivalence between a generic and an innovator product is based on the observed per-protocol (PP) population (usually completers and compliers). However, missing data and noncompliance are post-randomization intercurrent events and may introduce selection bias. Therefore, PP analysis is generally not causal. The FDA Missing Data Working Group recommended using “causal estimands of primary interest.” In this paper, we propose a principal stratification causal framework and co-primary causal estimands to test equivalence, which was also recommended by the recently published ICH E9 (R1) addendum to address intercurrent events. We identify three conditions under which the current PP estimator is unbiased for one of the proposed co-primary causal estimands – the “Survivor Average Causal Effect” (SACE) estimand. Simulation shows that when these three conditions are not met, the PP estimator is biased and may inflate Type 1 error and/or change power. We also propose a tipping point sensitivity analysis to evaluate the robustness of the current PP estimator in testing equivalence when the sensitivity parameters deviate from the three identified conditions, but stay within a clinically meaningful range. Our work is the first causal equivalence assessment in equivalence studies with intercurrent events.  相似文献   
3.

Background

Pharmacists need to demonstrate knowledge of and have confidence in Food and Drug Administration (FDA) therapeutic equivalence (TE) standards to improve acceptance of generic medicines amongst patients and other healthcare professionals.

Objective

To evaluate community pharmacists' understanding, interpretation and perceptions of the FDA TE standards to identify if further education is needed on this topic.

Methods

An anonymous, 13-item survey was piloted and then distributed by e-mail to a random sample of 287 Indiana community pharmacists. The 5-min survey included demographic, knowledge-based, and perception-based questions on FDA TE criteria that participants were given one week to complete. Participants completed the survey using a Web-based survey tool (Qualtrics).

Results

192 pharmacists completed the survey achieving a response rate of 66.9%. Only 7.3% of respondents correctly identified FDA bioequivalence criteria for approval of generic drug products. Two questions presented TE codes from the Orange Book and asked respondents to identify if a pair of drug products were therapeutically equivalent: 62.6% and 61.0% of respondents answered correctly. However, 89.4% of respondents correctly indicated that the Orange Book is the location of FDA TE evaluations. 74.9% of responding pharmacists indicated a positive perception of the rigor of FDA approval standards associated with generic medications and 66.0% believed that generic drug products made by different manufacturers are of similar quality.

Conclusions

The results suggest that community pharmacists need additional education on the interpretation of TE codes and FDA bioequivalence criteria for approval of generic drug products. The safety and efficacy of generics are often questioned by patients and physicians. It is important for pharmacists to be knowledgeable of FDA TE standards as they are experts in medicines and need to be confident with the criteria to effectively convey them to patients and healthcare professionals.  相似文献   
4.
Introduction: Generic inhalers are often perceived as inferior to their branded counterparts; however, they are safe and effective if they can meet the regulatory requirements. The approach to assess bioequivalence (BE) in oral dosage form products is not sufficient to address the complexities of inhalational products (e.g., patient-device interface); hence, more considerations are needed and caution should be applied in determining BE of inhaled compounds.

Areas covered: This review outlines the evaluation process for generic inhalers, explores the regulatory approaches in BE assessment, and highlights the considerations and challenges in the current in vitro and in vivo approaches (lung deposition, pharmacokinetic, pharmacodynamic/clinical studies, and patient-device interface) for establishing BE of inhaled compounds.

Expert opinion: The ultimate goals in this field are to establish uniformity in the regulatory approaches to speed the drug submission process in different regions, clear physicians’ misconception of generic inhalers, and have meaningful clinical endpoints such as improvement in patient quality of life when compared to placebo and brand name drugs. As inhalational drugs become more common for other indications such as antibiotics, the technologies developed for inhaled compounds in the treatment of chronic pulmonary diseases may be extrapolated to these other agents.  相似文献   

5.
SUMMARY

Objective: To investigate whether crushed or dissolved tablets of the oral direct thrombin inhibitor ximelagatran are bioequivalent to whole tablet administration. Ximelagatran is currently under development for the prevention and treatment of thromboembolic disorders.

Research design and methods: This was an open-label, randomised, three-period, three-treatment crossover study in which 40 healthy volunteers (aged 20–33 years) received a single 36-mg dose of ximelagatran administered in three different ways: I swallowed whole, II crushed, mixed with applesauce and ingested and III dissolved in water and administered via nasogastric tube.

Results: The plasma concentrations of ximelagatran, its intermediates and the active form melagatran were determined. Ximelagatran was rapidly absorbed and the bioavailability of melagatran was similar after the three different administrations, fulfilling the criteria for bioequivalence. The mean area under the plasma concentration-versus-time curve (AUC) of melagatran was 1.6μmol-h/l_ (ratio 1.01 for treatment II/I and 0.97 for treatment III/I), the mean peak concentration (Cmax) was 0.3μmol/L (ratio 1.04 for treatment II/I and 1.02 for treatment III/I) and the mean half-life (t1/2) was 2.8?h for all treatments. The time to Cmax (tmax) was 2.2?h for the whole tablet and approximately 0.5?h earlier when the tablet was crushed or dissolved (1.7–1.8?h), due to a more rapid absorption. The study drug was well tolerated as judged from the low incidence and type of adverse events reported.

Conclusion: The present study showed that the pharmacokinetics (AUC and Cmax) of melagatran were not significantly altered whether ximelagatran was given orally as a crushed tablet mixed with applesauce or dissolved in water and given via nasogastric tube.  相似文献   
6.
This study investigates the robustness of Schuirmann's two one-sided tests procedure under a set of Box-Cox alternatives. A simulation is conducted to study the level of significance and the power of the procedure. Empirical results show that Schuirmann's procedure is robust under Box-Cox alternatives when the mean of the underlying distribution of the reference formulation is known, which suggests that the assumptions of normality or lognormality are sufficient but may not be necessary. It appears that Schuirmann's procedure cannot maintain the proper level of significance when the mean of the reference formulation is unknown, even under the normality or lognormality assumptions.  相似文献   
7.
Bioequivalence trials are commonly conducted to assess therapeutic equivalence between a generic and an innovator brand formulations. In such trials, drug concentrations are obtained repeatedly over time and are summarized using a metric such as the area under the concentration vs. time curve (AUC) for each subject. The usual practice is to then conduct two one-sided tests using these areas to evaluate for average bioequivalence. A major disadvantage of this approach is the loss of information encountered when ignoring the correlation structure between repeated measurements in the computation of areas. In this article, we propose a general linear model approach that incorporates the within-subject covariance structure for making inferences on mean areas. The model-based method can be seen to arise naturally from the reparameterization of the AUC as a linear combination of outcome means. We investigate and compare the inferential properties of our proposed method with the traditional two one-sided tests approach using Monte Carlo simulation studies. We also examine the properties of the method in the event of missing data. Simulations show that the proposed approach is a cost-effective, viable alternative to the traditional method with superior inferential properties. Inferential advantages are particularly apparent in the presence of missing data. To illustrate our approach, a real working example from an asthma study is utilized.  相似文献   
8.
目的:建立测定血浆中苯磺酸左氨氯地平质量浓度的高效液相色谱-串联质谱(HPLC—MS/MS)法,研究苯磺酸左氨氯地平片的相对生物利用度及其生物等效性。方法:按照两制剂、双周期、自身对照、交叉试验设计,20例健康男性志愿者单剂量口服试验试剂或参比试剂,采用LC-MS/MS法测定血浆中苯磺酸左氨氯地平的药物质量浓度,使用WinNonlin6.1软件的NCA模块计算药动学参数,并评价2种制剂的生物等效性。结果:受试试剂及参比试剂的主要药代动力学参数如下:峰浓度(Cmax)分别为(3.37±1.9)、(3.50±1.39)μg·L^-1;峰时间(k)分别为(4.7±2.1)、(5.7±2.8)h;AUC妇(AUC0-t)分别为(146.3±53.5)、(144.1±43.3)μg·L^-1·L^-1;AUCW(AUC0-∞)分另4为(167.9±64.8)、(165.1±52.3)μg·L^-1·L^-1;AUCk;/AUCinf分另4为(87.8±6.1)%、(87.8±6.1)%;MRTlast(MRT0-t)分另4为(40.4±4.4)、(40.0±3.6)h;MRTinf(MRT0-∞)分另4为(57.5±13.6)、(57.1±12.5)h;血浆半衰期(t1/2)分别为(38.6±9.4)、(38.8±9.4)h。受试试剂的相对生物利用度:Flan为(101.3±15.7)%,Finf为(101.2±15.9)%。结论:受试试剂和参比试剂具有生物等效性。  相似文献   
9.
目的:研究氯沙坦钾胶囊及其片剂在健康人体内的药动学特征,并评价两种制剂间的生物等效性.方法:20名健康男性志愿受试者随机交叉单剂量口服试验制剂和参比制剂50 mg,清洗期1周,LC-MS/MS法测定血浆氯沙坦和代谢物氯沙坦羧酸(E-3174)浓度.药代参数的计算与统计分析使用DAS2.0软件.结果:口服试验制剂和参比制剂后,受试者的氯沙坦和E-3174主要药代动力学参数如下:氯沙坦Cmax分别为(183.83±91.30),(176.45±93.97) μg·L-1;AUC0-t分别为(333.18±105.00),( 323.75±101.92) μg·h·L1;AUC0-∞分别为(344.88±104.15),(341.32±106.13) μg·h·-1;t1/2分别为(1.84±0.52),(1.99±0.60)h;tmax分别为(0.70±0.22),(0.98±0.62)h.E-3174 Cmax分别为(344.85±114.33),(329.95±106.42) μg·L-1;AUC0-t分别为(2 445.09±608.97),(2 332.54±564.72) μg·h·L-1;AUC0-∞分别为(2 503.45±612.62),(2 390.92±567.03) μg·h·L-1;t1/2分别为(4.17±0.49),(4.13±0.66)h;tmax分别为(3.14±0.72),(3.39±0.96)h.试验制剂氯沙坦钾胶囊中氯沙坦和E-3174相对生物利用度分别为( 104.9±20.7)%和(105.2±12.1)%.结论:本试验采用的氯沙坦钾胶囊和氯沙坦钾片为生物等效制剂.  相似文献   
10.
格列美脲分散片人体生物等效性研究   总被引:1,自引:1,他引:0       下载免费PDF全文
周伦 《中国药师》2012,15(3):320-323
目的:比较两种格列美脲制剂的人体生物等效性.方法:20名健康男性志愿者随机交叉口服单剂量格列美脲分散片(受试制剂)与格列美脲片(参比制剂)2 mg,采用HPLC-MS法测定血浆中格列美脲浓度,用DAS 2.1软件计算药动学参数和生物利用度.结果:口服格列美脲受试制剂与参比制剂后的药动学参数分别为Cmax( 135.4±40.3)和(146.5±39.2) ng·ml-1,tmax(3.2±1.2)和(2.8±0.9)h,t1/2(7.3±3.9)和(6.7±2.8)h,AUC0~36 (757.1±217.2)和(849.4±250.4 )ng·h·ml-1,AUC0~∞(784.0±217.4)和(871.5±265.2) ng·h·ml-1.受试制剂的相对生物利用度为(90.7±17.5)%.结论:两种格列美脲制剂具有生物等效性.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号